MedTrace Logo

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test

NCT04549467 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2024-02-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of DTG + 3TC versus DTG + TDF/FTC over 48 weeks in HIV-1 naive patients in a real life setting with no baseline HIV genotypic resistance testing available.

Conditions

Interventions

DRUG

Lamivudine 300 MG

Experimental arm

DRUG

Emtricitabine / Tenofovir Disoproxil Pill

Active Comparator

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • Fundacion IDEAA

    lead OTHER

Principal Investigators

  • Ezequiel Cordova, MD · Fundacion IDEAA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-17
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04549467 on ClinicalTrials.gov